Introduction
A FODMAP-gentle diet has been proposed as a less restrictive alternative to the traditional low FODMAP diet for irritable bowel syndrome (IBS), but evidence on its effectiveness and safety remains uninvestigated.
Aims & Methods
We aim to evaluate the efficacy of a FODMAP-gentle diet in tertiary-care IBS, evaluating gastrointestinal symptoms, nutritional intake, weight change, avoidant/restrictive food intake disorder (ARFID) symptoms and psychosocial outcomes.
Patients with IBS completed a 2-week baseline period followed by an 8-week FODMAP-gentle diet, delivered through the DOMINO app, combining traditional dietary advice by the NICE guidelines with FODMAP-light principles. Daily symptom diaries assessed severity of abdominal pain, bloating, flatulence, daily symptom impact, and stool habits using the Bristol Stool Scale (BSS). Seven-day food diaries were collected at baseline and during diet. IBS symptom severity (IBS-SSS), ARFID symptoms (NIAS defined meeting ≥1 subscale cutoff (Picky Eating ≥10, Appetite ≥9, Fear ≥10) combined with DSM-5 impairment), and psychosomatic comorbidity questionnaires (PHQ-9/15, GAD-7) were completed at baseline and after diet.
Results
Among 72 tertiary care patients with IBS (75% female, 34 (27-45) years old, BMI 24 (22-28) kg/m²), the DOMINO app diet significantly reduced IBS-SSS (270 (220-330) vs. 150 (103-210), p < 0.0001) with a 76% responder rate (≥ 50 points improvement). Daily symptom diaries (table 1) demonstrated significant reductions in severity of abdominal pain, bloating, flatulence, and daily symptom impact (all p < 0.001). Compared to baseline, normal stools (BSS 3–5) increased, soft stools (BSS 6–7) and urgency episodes decreased (all p < 0.01) after diet. Caloric intake decreased minimally after diet (−160 (−350-60) kcal/day, p < 0.001), but no weight loss was observed. Total FODMAP intake decreased from 12 (10-18) to 8 (5-13) g/day, p < 0.0001. Quality of life and psychosocial measures improved significantly, including extraintestinal symptoms, depression, and anxiety (all p ≤ 0.01). At baseline, 21% met criteria for ARFID, decreasing to 18% after the diet (p < 0.001). Five participants developed new ARFID-like symptoms, while eight remitted (p = 0.58). Compared to baseline, picky eating scores remained stable, while appetite and fear scores decreased after diet (p < 0.05).
| IBS symptoms | Baseline | Diet | p value |
| Severity abdominal pain | 34 (23-45) | 12 (7-26) | < 0.001 |
| Bloating | 42 (26-54) | 13 (7-25) | < 0.001 |
| Flatulence | 40 (27-55) | 14 (9-27) | < 0.001 |
| Daily symptom impact | 34 (20-44) | 11 (6-27) | < 0.001 |
| Stool diary |
|
|
|
| Hard stools | 1 (0-5) | 1 (0-4) | 0.96 |
| Normal stools | 10 (6-14) | 12 (9-16) | < 0.001 |
| Soft stools | 4 (1-7) | 1 (0-2) | < 0.001 |
| Stool urgency | 2 (1-4) | 1 (0-2) | < 0.001 |
Table 1. Comparison between IBS symptoms and stool pattern at baseline vs diet. IBS symptoms are scored on a 0-100 mm visual analogue scale. Stools are reported as days per Bristol Stool Scale (BSS) types over two weeks, categorized as hard (type 1 and 2), normal (type 3, 4 and 5) or soft stools (type 6 and 7).
Conclusion
The FODMAP-gentle DOMINO diet app resulted in significant improvements in IBS symptoms, stool consistency, quality of life, and psychosocial wellbeing in tertiary-care patients with IBS. The diet is safe, showing no clinically significant reductions in caloric intake and body weight, and did not increase ARFID risk. These findings support the FODMAP-gentle DOMINO app approach as an effective and safe dietary strategy for IBS management.